The Impact of Your Support

Together, We're Advancing COVID-19 Research

From antibody discovery to vaccine trials, your support is driving progress.

Fueled by your donation, research to understand the coronavirus and end the pandemic is happening at a scale and speed that none of us could have imagined a year ago. With your help, we opened a unique clinical research center to test therapies with the potential to stop COVID-19 before symptoms become debilitating or deadly. We are leading large-scale vaccine trials, isolating antibodies that neutralize the virus, and decoding the immune system’s response to coronavirus infection. Thanks to you, we are applying 45 years of expertise to solve a completely new problem — and we are making tangible progress.

Your belief in science — and your support of our work — makes all this possible. We are grateful, and we're proud to share how your generosity is helping to stop the pandemic.

Hayley Glantz working in McElrath Lab
Hayley Glantz, a research technician in Dr. Julie McElrath's lab, works with COVID-19 samples. Photo by Jake Siegel

Philanthropy makes it possible for science to move at the speed of the pandemic.

Your Investment is Fueling Research

Our researchers are playing a leading role in the international scientific response to the pandemic: exploring how the virus could mutate to escape detection by the immune system, creating complex computer models to understand viral transmission and super-spreading events, assessing the impact of COVID-19 on patients with cancer and underserved populations, and more. We’re also leading a campaign to ensure groups that face the highest risk of severe infection and death from COVID-19 are equitably represented in vaccine trials.

Your investment in the COVID-19 Research Fund has enabled scientists across Fred Hutch to move at record speed to tackle formidable challenges from many angles. Highlights include:

COVID-19 Clinical Research Center

Seattle COVID-19 Cohort Study

Finding Coronavirus-Targeting Antibodies

COVID-19 Vaccines in Cancer Patients

COVID-19 Clinical Research Center

Philanthropic donations and public-private partnerships enabled us to rapidly transform a building on our campus into the COVID-19 Clinical Research Center (CCRC) at Fred Hutch. The CCRC, which opened in September, is one of the first stand-alone facilities in the nation designed to test antiviral drugs, monoclonal antibodies, and other therapies for people who are at risk for, newly diagnosed with, or recovering from COVID-19. Much like our Bezos Family Immunotherapy Clinic (the first-ever facility devoted to clinical trials of immune-based therapies for patients with cancer), this is a unique collaborative space for scientists and clinicians to partner with study volunteers, health care providers, research institutes, foundations, and the biotech/pharmaceutical industry researchers on clinical trials. View current studies.

Medical Director

Dr. Rachel Bender Ignacio, associate, Fred Hutch Vaccine and Infectious Disease Division; assistant professor, University of Washington Department of Medicine

Donor-Funded Pilot Awards

Your gift makes it possible to test outside-the-box ideas that are not yet ready for foundation or government funding. Donor-funded pilot awards allow scientists to generate the proof of concept they need to attract larger grants — and they are critical to jump-starting the most innovative projects. Thanks to you, the investigators listed below have received donor-funded COVID-19 pilot awards. 

Dr. Jim Boonyaratanakornkit

Research Associate, Vaccine and Infectious Diseases Division

Dr. Boonyaratanakornkit in the Taylor Lab is investigating how cells that have previously produced antibodies in response to common cold-causing coronaviruses influence infection by the pandemic-causing SARS-CoV-2 virus. His goal is to design 2-for-1 strategies that can protect people from both types of coronaviruses.

Dr. Neelendu Dey

Assistant Professor, Clinical Research Division

Dr. Dey’s project is a “fail fast” study of whether it might be possible to target the microbiome to help patients recover more quickly or reduce the virus's chance of spreading through fecal transmission.

Dr. Taran Gujral

Assistant Professor, Human Biology Division

Dr. Gujral is employing new machine-learning methods to learn how the coronavirus causes immune cells to trigger “cytokine storms,” the cause of respiratory failure in severe cases in COVID-19, and to pinpoint potential treatments.

Dr. Linda Ko

Assistant Professor, Public Health Sciences Division

Dr. Ko is leveraging her long-standing research partnerships with community-based organizations to evaluate the impact of COVID-19 on their ability to deliver lifeline services to older adults in the Asian American and Pacific Islander community. This project, which aims to inform strategies to improve health equity, is funded by the Vadon Foundation.

Dr. Jim Kublin

Principal Staff Scientist, Vaccine and Infectious Disease Division

Dr. Kublin’s team is studying microbes in the gut and respiratory tract of COVID-19 patients to look for a correlation between patients’ microbiomes and their clinical outcomes.

Dr. Vivian Oehler

Associate Professor, Clinical Research Division

Dr. Oehler is testing a broad panel of FDA-approved cancer drugs against COVID-19 to find treatments that could be effective in early-stage infection.

Dr. Julie Overbaugh

Professor, Human Biology and Public Health Sciences division; Endowed Chair for Graduate Education

Dr. Overbaugh’s team is exploring cells’ innate defenses to learn how the coronavirus overcomes these barriers, and to find ways to bolster them.

Dr. Parth Shah

Assistant Professor, Public Health Sciences Division

Pharmacies play a critical role in patients’ health, especially in rural and low-income areas. Dr. Shah’s team is evaluating a new, pharmacy-based COVID-19 testing program in Washington, with a goal of increasing this vital health service in communities hit hard by the virus.   

Dr. Barry Stoddard

Professor, Basic Sciences Division

Dr. Stoddard is testing whether a unique “three-peat” protein design can stimulate a more robust immune response to coronavirus than current methods being used to develop a vaccine.   

Dr. Alpana Waghmare

Associate, Vaccine and Infectious Disease Division

Using a simple and safe home blood collection method, Dr. Waghmare is obtaining samples from patients with suspected COVID-19 to hunt for molecular signatures that correlate with disease severity.


COVID-19 Vaccine Trials

Fred Hutch is coordinating large-scale vaccine trials for the COVID-19 Prevention Network (CoVPN ), part of a monumental, government-led effort to test, develop, and distribute coronavirus vaccines in record time. The NIH chose Fred Hutch for this pivotal role because we were ready: We’ve been recruiting experts, pioneering new vaccine strategies, building trust in the community, and running complex trials for more than two decades through our HIV Vaccine Trials Network, the world’s largest international collaboration to develop vaccines that protect against HIV.

This expertise, combined with our COVID-19 research, puts us in a unique position us to take on this immense challenge — and we’re eager to do it.

$10+ M

Raised to Date
Your generous support is fueling critical research.


Nearly half are new donors.

$10 M

Fundraising Goal
Thank you for helping us reach our ambitious goal.

Support From Across the Community — and Beyond

Our supporters — individuals and organizations around the country — are investing in science that will lead us out of the current crisis and help us prepare for the next one. We are grateful to longtime donors to our cancer research, who recognize the urgency of coronavirus research and have responded generously. We’re equally heartened that nearly half the gifts we’ve received come from new supporters who chose to fuel scientific discovery by supporting Fred Hutch. Here’s a snapshot of support for our COVID-19 research (please check back for updates):

Donor Map
Dashboard provided by Tableau

Longtime Supporters
Many of our longtime supporters have come forward in extraordinary ways to fuel our COVID-19 research. For example, the Bezos family sponsored our Return to Campus Study, which has  helped to keep our campus COVID-free. Seattle philanthropists Gwenn and Dean Polik donated $100,000 through their family foundation — their largest-ever gift to the Hutch. Beth McCaw and Yahn Bernier provided a $500,000 match for donations made on #GivingTuesdayNow/GiveBIG, inspiring thousands of others to give. Will and Cassandra Arora invested $25,000 in retrofitting our new COVID-19 Clinical Research Center because, as Will said, “This is a unique time, and we want to be part of the solution.”

Grassroots Supporters
Gifts of every size matter. Nearly 60% of gifts we have received for COVID-19 research are under $100. Together, these gifts add up to nearly $25,000. More than 1,200 people gave a total of $809,000 through the #GivingTuesdayNow/GiveBIG campaigns last spring (that’s in addition to the generous match mentioned above). Our wonderful supporters have also donated thousands of homemade face masks, gallons of hand sanitizer, and other valuable in-kind contributions — and one family donated $1,000 that they had planned to spend on a Disney World vacation.

Corporate Partners 
We’re grateful to businesses and corporations that, while managing their own responses to the pandemic, have contributed to our research. A $500,000 gift from Bank of America accelerated our efforts to probe the immune response to COVID-19 and enabled our clinical care partner, Seattle Cancer Care Alliance (SCCA), to invest in PPE and specialized safety equipment. JPMorgan Chase donated $45,000 to our COVID-19 research, along with $30,000 for our general operations. Through its #givetogether initiative, Microsoft matched its employees’ donations in April and May, doubling the impact of their support for COVID-19 relief efforts. Amazon is sponsoring CovidWatch, a study led by Dr. Michael Boeckh, head of our Infectious Disease Sciences Program, and AWS donated nearly $100,000 in cloud credits for data-intensive COVID-19 research. UMC donated $15,000, Baird Foundation gave $5,000, and longtime corporate partners Lease Crutcher Lewis and Prime Electric also contributed to our COVID-19 Research Fund.

Foundation Support
A $350,000 gift from the M.J. Murdock Charitable Trust helped launch two COVID-19 research projects: one to increase capacity and speed of testing for the coronavirus, and one to discover neutralizing antibodies that can stop the virus in its tracks. A generous $100,000 gift from the Vadon Foundation is supporting research into COVID-19 health inequities and the pandemic's disproportionate effect on communities of color. The Anderson Foundation invested $100,000 in our COVID-19 research, and a $50,000 grant from Emergent Ventures, through its COVID-19 Fast Grants initiative, is funding a vaccine project.

Innovators Network Challenge
The governing council of Innovators Network, our giving club for young professionals, challenged members to raise $100,000 for COVID-19 research — and they exceeded their goal! 

We reimagined Obliteride 2020 as a season of sweat, fun, and community — all from a safe distance. And our incredible community delivered. Participants joined from all 50 states and all seven continents — and raised $3.1 million for COVID-19 and cancer research. We are grateful to the participants, donors, teams, sponsors, corporate partners, and other friends who made this an Obliteride to remember. And we are particularly grateful for the support of GLY Construction: In addition to being an Obliteride Cheer Squad sponsor, GLY made a generous donation that allowed SCCA to purchase 3,000 N95 masks for its providers.

Creative Community Response

We’ve been amazed and impressed by the inventive ways people are using their unique skills and interests to work fuel COVID-19 research — all while sheltering at home. Here are a few examples:

Coaches vs. COVID Twitter live Zoom meeting.

Coaches vs. COVID

Tanner Swanson, a catching coach for the New York Yankees, supports Fred Hutch in memory of his sister, who died of breast cancer in 2018. When COVID-19 started to spread, he hit on a way to keep the coaching community connected while supporting our coronavirus research. Through Coaches vs. COVID, Tanner and fellow MLB coaches hosted virtual skills clinics for fellow baseball coaches at all levels. The cost? A donation to Fred Hutch. Coaches vs. COVID launched March 31 and blew past its $25,000 goal in early May.

Bingothon – Gaming For Charity


While the pandemic hasn’t disrupted the charity gaming stream Bingothon’s semi-annual marathon events (which have always been virtual), it did inspire its organizers to support COVID-19 research with this year’s proceeds. They chose Fred Hutch as the recipient of their funds because we are home to Dr. Trevor Bedford, co-founder of Nextstrain, an open-source tool that enables scientists around the world to share genetic data about the virus in real time. Bingothon’s May marathon raised more than $2,000 for our COVID-19 Research Fund — and proceeds from its winter event will also benefit Fred Hutch.


Support COVID-19 Research

Fred Hutch COVID-19 Research in the News

All COVID-19 Media Coverage

From the earliest days of the COVID-19 pandemic, Fred Hutch scientists have been sharing their expertise through interviews and conversations with reporters and media outlets including the New York TimesThe Wall Street Journal, the Seattle TimesNPR and others. See a list of some of the significant coverage.